Strategic Collaborators
Vie Ventures at FASI-10 Summit
Challenges and Opportunities in Food Allergy Drug Development
JP Morgan Week | 1/11/2026 | San Francisco
Steven St. Peter, M.D., Founder and Managing Director of Vie Ventures, joined the Food Allergy Science Initiative’s FASI-10 Summit on October 7th, 2026, for a panel on the challenges and opportunities in food allergy drug development, moderated by FASI’s CEO, Carlos Bosques, Ph.D.
- During the discussion, Steven highlighted why looking across disease areas matters: therapies developed for another disease could ultimately have meaningful applications in food allergy.
- For families focused on food allergy, supporting progress can include looking beyond that disease for promising approaches. This perspective reflects Vie’s interest in connecting disease-focused expertise and philanthropy with therapeutic development across diseases.
- Watch the segment above for Steven’s perspective on allergen-specific and allergen-agnostic therapies, and why potential advances may come from beyond food allergy.